Mecanismes moleculars implicats en la interacció dels receptors cel·lulars herpes simplex entry mediator A (HveA) i receptor de complement 2 (CR2, CD21) amb els seus lligands

Consultable des del TDXTítol obtingut de la portada digitalitzadaL'estudi de la utilització del sistema immunològic de l'hoste pels virus com a patògens per al seu propi benefici fou el principal objectiu d'aquest treball. Concretament, en aquest treball de tesis es van analitzar dues espècies d'herpesvirus virulents en humans, l'Herpes Simplex Virus-1 (HSV-1) i l'Epstein Barr Virus (EBV). L'entrada d'ambdós virus a les cèl·lules és mediada per receptors del sistema immunològic. Es va estudiar la interacció dels respectius receptors cel·lulars, Herpes Virus Entry mediator A (HveA), i el receptor de complement 2 (CR2), amb les glicoproteïnes virals que s'hi uneixen, i amb llurs lligands naturals, els quals participen en la defensa de l'hoste. Es va caracteritzar la interacció dels receptors HveA i CR2 amb els seus lligands fent servir proteïnes recombinants o purificades de sèrum; en el cas de HveA ens vam centrar en la localització del lloc d'unió de cada lligand al receptor. En el cas de CR2, es va analitzar la cinètica d'unió dels seus lligands naturals. Per a ambdós receptors, es va analitzar si la unió de la proteïna viral al receptor podria interferir i/o modular-ne la unió dels seus lligands naturals. Els resultats es van analitzar dins del marc de la resposta immunològica de l'hoste mediada pel receptor cel·lular, i en relació al possible paper modificador d'aquesta resposta per part de la proteïna viral. Per a facilitar el nostre estudi sobre HveA, es van cercar nous lligands peptídics d'aquest receptor, utilitzant llibreries aleatòries de pèptids expressades en el fag M13. Es van aïllar dos pèptids, i es va estudiar la seva interacció amb el receptor i la seva capacitat d'inhibir l'entrada del virus a les cèl·lules, és a dir, com a possibles agents terapèutics.Our goal in the present work was to study the manipulation of the host immune system by an infecting virus to its own benefit. Specifically, we studied two herpes viruses; Herpes Simplex Virus-1 (HSV-1) and Epstein Barr Virus (EBV), which infect humans. Entry of both viruses into the cell is mediated by the interaction of a specific viral surface glycoprotein with two receptors that participate in the host immune response, the Herpes Virus Entry mediator A (HveA), and complement receptor 2 (CR2). We studied the interaction of these receptors with the viral glycoproteins as well as their host ligands. The latter play a role in the immune response of the host. We characterized these interactions by using recombinant as well as serum-purified proteins. Our study of HveA sought to localize the specific binding site of each ligand on the receptor, while that of CR2 consisted in the kinetic analysis of its interaction with its ligands. We also analyzed whether binding of the viral glycoprotein to each receptor would interfere or modulate its interaction with its host ligands. Our results were analyzed in the context of the role of these receptors in the host immune response, and specifically whether the viral proteins studied undermined the host's ability to defend itself from infection. To study the relationship between HveA, its natural ligands, and the viral proteins involved in HSV entry, we also screened two phage-displayed combinatorial peptide libraries for peptide ligands of a recombinant form of HveA. We isolated two peptides, and studied their interaction with HveA as well as their ability to block HSV entry into HveA-bearing cells

Reduced plasma extracellular vesicle CD5L content in patients with acute-on-chronic liver failure: interplay with specialized pro-resolving lipid mediators.

Acute-on chronic liver failure (ACLF) is a syndrome that develops in patients with acutely decompensated cirrhosis (AD). It is characterized by a systemic hyperinflammatory state, leading to multiple organ failure. Our objective was to analyze macrophage anti-inflammatory protein CD5L in plasma extracellular vesicles (EVs) and assess its as yet unknown relationship with lipid mediators in ACLF. With this aim, EVs were purified by size exclusion chromatography from the plasma of healthy subjects (HS) (n=6) and patients with compensated cirrhosis (CC) (n=6), AD (n=11) and ACLF (n=11), which were defined as positive for CD9, CD5L and CD63 and their size, number, morphology and lipid mediator content were characterized by NTA, EM, and LC-MS/MS, respectively. Additionally, plasma CD5L was quantified by ELISA in 10 HS, 20 CC and 149 AD patients (69 ACLF). Moreover, macrophage CD5L expression and the biosynthesis of specialized lipid mediators (SPMs) were characterized in vitro in primary cells. Our results indicate that circulating EVs were significantly suppressed in cirrhosis, regardless of severity, and showed considerable alterations in CD5L and lipid mediator content as the disease progressed. In AD, levels of EV CD5L correlated best with those of the SPM RvE1. Analysis of total plasma supported these data and showed that, in ACLF, low CD5L levels were associated with circulatory (p<0.001), brain (p<0.008) and respiratory (p<0.05) failure (Mann-Whitney test). Functional studies in macrophages indicated a positive feedback loop between CD5L and RvE1 biosynthesis. In summary, we have determined a significant alteration of circulating EV contents in ACLF, with a loss of anti-inflammatory and pro-resolving molecules involved in the control of acute inflammation in this condition

Identification of the most vulnerable populations in the psychosocial sphere: a cross-sectional study conducted in Catalonia during the strict lockdown imposed against the COVID-19 pandemic.

Design and objectives A cross-sectional study to evaluate the impact of COVID-19 on the psychosocial sphere in both the general population and healthcare workers (HCWs). Methods The study was conducted in Catalonia (Spain) during the first wave of the COVID-19 pandemic when strict lockdown was in force. The study population included all people aged over 16 years who consented to participate in the study and completed the survey, in this case a 74-question questionnaire shared via social media using snowball sampling. A total of 56 656 completed survey questionnaires were obtained between 3 and 19 April 2020. The primary and secondary outcome measures included descriptive statistics for the non-psychological questions and the psychological impact of the pandemic, such as depression, anxiety, stress and post-traumatic stress disorder question scores. Results A n early and markedly negative impact on family finances, fear of working with COVID-19 patients and ethical issues related to COVID-19 care among HCWs was observed. A total of seven target groups at higher risk of impaired mental health and which may therefore benefit from an intervention were identified, namely women, subjects aged less than 42 years, people with a care burden, socioeconomically deprived groups, people with unskilled or unqualified jobs, patients with COVID-19 and HCWs working with patients with COVID-19. Conclusions Active implementation of specific strategies to increase resilience and to prepare an adequate organisational response should be encouraged for the seven groups identified as high risk and susceptible to benefit from an intervention

The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD metabolism

Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway

Mecanismes moleculars implicats en la interacció dels receptors cel·lulars herpes simplex virus entry mediator A (HveA) i receptor de complement 2 (CR2, CD21) amb els seus lligands

L'estudi de la utilització del sistema immunològic de l'hoste pels virus com a patògens per al seu propi benefici fou el principal objectiu d'aquest treball. Concretament, en aquest treball de tesis es van analitzar dues espècies d'herpesvirus virulents en humans, l'Herpes Simplex Virus-1 (HSV-1) i l'Epstein Barr Virus (EBV). L'entrada d'ambdós virus a les cèl.lules és mediada per receptors del sistema immunològic. Es va estudiar la interacció dels respectius receptors cel.lulars, Herpes Virus Entry mediator A (HveA), i el receptor de complement 2 (CR2), amb les glicoproteïnes virals que s'hi uneixen, i amb llurs lligands naturals, els quals participen en la defensa de l'hoste. Es va caracteritzar la interacció dels receptors HveA i CR2 amb els seus lligands fent servir proteïnes recombinants o purificades de sèrum; en el cas de HveA ens vam centrar en la localització del lloc d'unió de cada lligand al receptor. En el cas de CR2, es va analitzar la cinètica d'unió dels seus lligands naturals. Per a ambdós receptors, es va analitzar si la unió de la proteïna viral al receptor podria interferir i/o modular-ne la unió dels seus lligands naturals. Els resultats es van analitzar dins del marc de la resposta immunològica de l'hoste mediada pel receptor cel·lular, i en relació al possible paper modificador d'aquesta resposta per part de la proteïna viral. Per a facilitar el nostre estudi sobre HveA, es van cercar nous lligands peptídics d'aquest receptor, utilitzant llibreries aleatòries de pèptids expressades en el fag M13. Es van aïllar dos pèptids, i es va estudiar la seva interacció amb el receptor i la seva capacitat d'inhibir l'entrada del virus a les cèl·lules, és a dir, com a possibles agents terapèutics.Our goal in the present work was to study the manipulation of the host immune system by an infecting virus to its own benefit. Specifically, we studied two herpes viruses; Herpes Simplex Virus-1 (HSV-1) and Epstein Barr Virus (EBV), which infect humans. Entry of both viruses into the cell is mediated by the interaction of a specific viral surface glycoprotein with two receptors that participate in the host immune response, the Herpes Virus Entry mediator A (HveA), and complement receptor 2 (CR2). We studied the interaction of these receptors with the viral glycoproteins as well as their host ligands. The latter play a role in the immune response of the host. We characterized these interactions by using recombinant as well as serum-purified proteins. Our study of HveA sought to localize the specific binding site of each ligand on the receptor, while that of CR2 consisted in the kinetic analysis of its interaction with its ligands. We also analyzed whether binding of the viral glycoprotein to each receptor would interfere or modulate its interaction with its host ligands. Our results were analyzed in the context of the role of these receptors in the host immune response, and specifically whether the viral proteins studied undermined the host's ability to defend itself from infection. To study the relationship between HveA, its natural ligands, and the viral proteins involved in HSV entry, we also screened two phage-displayed combinatorial peptide libraries for peptide ligands of a recombinant form of HveA. We isolated two peptides, and studied their interaction with HveA as well as their ability to block HSV entry into HveA-bearing cells

A role for human Sp alpha as a pattern-recognition receptor

Human Sp alpha is a soluble protein belonging to group B of the scavenger receptor cysteine-rich (SRCR) superfamily for which little functional information is available. It is expressed by macrophages present in lymphoid tissues (spleen, lymph node, thymus, and bone marrow), and it binds to myelomonocytic and lymphoid cells, which suggests that it may play an important role in the regulation of the innate and adaptive immune systems. In the present study we show that recombinant human Sp alpha (rSp alpha) binds to the surface of several gram-positive and gram-negative bacterial strains. Competition studies indicated that such binding is mediated by the recognition of lipoteichoic acid (LTA) and lipopolysaccharide (LPS), respectively, through nonoverlapping sites on the Sp alpha molecule. The most conserved part of LPS (2-keto-3-deoxyoctulosonic acid and lipid A) was shown to be involved in the recognition by Sp alpha. Bacterial binding studies using the SRCR domain 1 of Sp alpha showed that this domain retains both the LPS and LTA binding activities, indicating that both bacterial interacting sites are retained in a single SRCR domain. Furthermore, rSp alpha induced aggregation of gram-positive and gram-negative bacteria strains. On the other hand, rSp alpha inhibited tumor necrosis factor-alpha secretion by human monocytes stimulated with LPS or LTA. Binding of Sp alpha to conserved components of bacterial surfaces and modulation of the monocyte response indicate that this molecule is an active constituent of the innate immune response of the host

The Nuclear Receptor LXR Limits Bacterial Infection of Host Macrophages through a Mechanism that Impacts Cellular NAD Metabolism

Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of non-opsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bone-marrow-derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway.This work was supported by grants from the Spanish MICINN to A.F.V. (SAF2010-14989, SAF2011-23402, and SAF2014-57856), R.V. (SAF2010-16725), and the NuRCaMeIn network (SAF2015-71878-REDT); from Fundació la Marató de TV3 to A.F.V. (080930) and R.V. (20134030); and from COST Action BM1404 (Mye-EUNITER). M.R.S. is a Miguel Servet II researcher (ISCIII CPII14/00021), and C.E. is supported by a grant from ANII (INNOVA II, FCE_1_2014_1_104002, Uruguay). J.M. received fellowships from the Spanish MICINN (FPI, BES-2009-014828) and from the Institut Pasteur-Pierre Ledoux Jeunesse Internationale Foundation, M.P. received fellowships from the Spanish MEC (FPU, AP 2007-00821), J.M.C. received fellowships from the UB (APIF), and M.B. received fellowships from ANII (Uruguay)

The nuclear receptor LXR limits bacterial infection of host macrophages through a mechanism that impacts cellular NAD metabolism

Macrophages exert potent effector functions against invading microorganisms but constitute, paradoxically, a preferential niche for many bacterial strains to replicate. Using a model of infection by Salmonella Typhimurium, we have identified a molecular mechanism regulated by the nuclear receptor LXR that limits infection of host macrophages through transcriptional activation of the multifunctional enzyme CD38. LXR agonists reduced the intracellular levels of NAD+ in a CD38-dependent manner, counteracting pathogen-induced changes in macrophage morphology and the distribution of the F-actin cytoskeleton and reducing the capability of nonopsonized Salmonella to infect macrophages. Remarkably, pharmacological treatment with an LXR agonist ameliorated clinical signs associated with Salmonella infection in vivo, and these effects were dependent on CD38 expression in bonemarrow- derived cells. Altogether, this work reveals an unappreciated role for CD38 in bacterial-host cell interaction that can be pharmacologically exploited by activation of the LXR pathway